Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$69.00 USD

69.00
3,383,003

-0.70 (-1.00%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $69.10 +0.10 (0.14%) 6:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks News

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

DexCom (DXCM) Crossed Above the 20-Day Moving Average: What That Means for Investors

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

DexCom's (DXCM) G7 Links With Tandem's Insulin Pump in Europe

Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.

DexCom (DXCM) Advances While Market Declines: Some Information for Investors

DexCom (DXCM) closed the most recent trading day at $125.45, moving +0.8% from the previous trading session.

Why DexCom (DXCM) Could Beat Earnings Estimates Again

DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

DexCom (DXCM) Gains As Market Dips: What You Should Know

The latest trading day saw DexCom (DXCM) settling at $128.93, representing a +0.73% change from its previous close.

DexCom (DXCM) Preliminary Q4 Revenues Ride on Sensor Demand

DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by strong demand for its CGM sensors across the globe. It delivers robust revenue guidance for 2024.

Here's Why DexCom (DXCM) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Moumi Mondal headshot

Wearable Technology Market Gains Ground, 3 Stocks in Focus

In the wearable medical devices industry, investors can keep a keen eye on stocks such as ABT, MDT and DXCM.

DexCom (DXCM) Exceeds Market Returns: Some Facts to Consider

DexCom (DXCM) closed at $123.98 in the latest trading session, marking a +1.76% move from the prior day.

Alcon (ALC) Business Hurt by Macroeconomic Woes, Competition

In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.

Thermo Fisher (TMO) End Markets Drive Growth Amid Macro Woes

In the academic and government end markets, Thermo Fisher (TMO) is delivering strong growth in the electron microscopy, chromatography and mass spectrometry businesses.

If You Invested $1000 in DexCom a Decade Ago, This is How Much It'd Be Worth Now

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Here's Why You Should Retain Edward Lifesciences (EW) Stock Now

Investors remain optimistic about Edward Lifesciences (EW) due to the strength of its product group.

Omnicell (OMCL) Gains From Innovation Amid Cost Pressure

Omnicell (OMCL) plans to focus on integrating customer success functions into its broader organizational structure.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

Investors remain optimistic about Teleflex (TFX), backed by the strong prospects of the Interventional business and stable solvency.

Boston Scientific (BSX) Initiates AVANT GUARD Clinical Trial

Boston Scientific's (BSX) AVANT GUARD clinical trial is set to evaluate the FARAPULSE PFA System as the first-line treatment for persistent AF.

DexCom (DXCM) Stock Moves -0.06%: What You Should Know

The latest trading day saw DexCom (DXCM) settling at $124.09, representing a -0.06% change from its previous close.

Globus Medical (GMED) Gains From Innovation Amid Macro Issues

Globus Medical (GMED) is particularly seeing notable gains in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

Investors remain optimistic about Labcorp (LH) due to impressive partnerships and expansion efforts in targeted high-growth areas.

Here's Why You Should Invest in Insulet (PODD) Stock for Now

Investors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position.

Here's Why You Should Retain Illumina (ILMN) Stock for Now

Investors are optimistic about Illumina's (ILMN) strength in the genomics market and strong solvency position.

National Vision (EYE) Store Openings Aid, Macro Issues Stay

In terms of store expansion, National Vision (EYE) continues to see sizable new opportunities for many years to come.